VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LABStandard BioTools Inc.
$0.54$223M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLABFinancials

Standard BioTools Inc. (LAB) Income Statement

20Y historyFree accessUpdated daily

Revenue has contracted sharply to $19.4M in 2026Q3 with gross margin ranging between 43.0% and 55.9%, yet operating margin of -102.0% indicates overhead reduction has not closed the profitability gap.

Income StatementBalance SheetCash FlowRatios

LAB Income Statement

Annual statement

LAB Income Statement

Standard BioTools Inc. (LAB) annual income statement — 20-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06
Sales/Revenue84.43M85.33M174.43M106.34M97.95M130.58M138.14M117.24M112.96M101.94M104.45M114.71M116.46M71.18M52.33M42.87M33.56M25.41M15.35M7.28M6.4M
Revenue Growth %-22.01%-51.08%64.03%8.57%-24.99%-5.47%17.83%3.79%10.82%-2.4%-8.95%-1.5%63.6%36.02%22.09%27.73%32.06%65.58%110.96%13.71%-
Cost of Goods Sold41.52M42.79M90.17M55.89M60.9M61.21M54.82M52.96M51.31M49.95M46.01M46.63M42.85M20.08M15.32M13.19M11.58M11.49M8.36M3.51M2.77M
COGS % of Revenue-50.14%51.69%52.56%62.17%46.87%39.68%45.17%45.43%49.01%44.05%40.65%36.79%28.21%29.28%30.77%34.51%45.2%54.5%48.3%43.34%
Gross Profit42.91M42.54M84.26M50.45M37.05M69.37M83.33M64.28M61.65M51.98M58.44M68.08M73.61M51.1M37.01M29.67M21.98M13.93M6.98M3.76M3.63M
Gross Margin %50.82%49.86%48.31%47.44%37.83%53.13%60.32%54.83%54.57%50.99%55.95%59.35%63.21%71.79%70.72%69.23%65.49%54.8%45.5%51.7%56.66%
Gross Profit Growth %--49.51%67.02%36.16%-46.59%-16.75%29.63%4.27%18.6%-11.05%-14.17%-7.51%44.04%38.08%24.72%35.01%57.83%99.43%85.67%3.75%-
Operating Expenses119.41M135.85M259.5M127.05M153.26M136.83M134.36M116.12M109.81M110.34M131.63M122.22M114.75M67.78M55.08M45.24M36.55M31.96M36.53M27.29M25.29M
OpEx % of Revenue-159.2%148.77%119.48%156.47%104.79%97.26%99.04%97.21%108.25%126.02%106.55%98.53%95.23%105.25%105.54%108.92%125.78%238%375.08%395.25%
Selling, General & Admin76.22M109.86M156.61M87.54M102.28M98.89M97.9M84.48M79.78M79.52M93.21M82.96M71.32M48.05M38.48M31.3M23.55M19.65M22.51M12.9M9.7M
SG&A % of Revenue-128.75%89.78%82.32%104.43%75.73%70.87%72.05%70.63%78%89.24%72.32%61.25%67.51%73.52%73.03%70.16%77.32%146.68%177.29%151.59%
Research & Development13.96M25.99M62.41M25.95M37.38M37.94M36.46M31.64M30.03M30.83M38.41M39.26M43.42M19.73M16.6M13.94M13.01M12.31M14.02M14.39M15.59M
R&D % of Revenue-30.45%35.78%24.4%38.17%29.06%26.39%26.99%26.58%30.24%36.78%34.23%37.29%27.72%31.72%32.51%38.76%48.46%91.32%197.79%243.65%
Other Operating Expenses2M040.48M13.56M13.59M000637K385K-1.17M-1.16M-857K502K-189K000000
Operating Income-76.5M-93.31M-175.24M-76.6M-116.2M-67.46M-51.04M-51.84M-48.16M-58.36M-73.19M-50.16M-51.84M-17.95M-18.07M-18.57M-14.57M-18.04M-29.54M-23.53M-21.66M
Operating Margin %-90.6%-109.34%-100.46%-72.03%-118.64%-51.66%-36.94%-44.21%-42.64%-57.25%-70.07%-43.72%-44.51%-25.22%-34.53%-43.31%-43.42%-70.98%-192.5%-323.38%-338.59%
Operating Income Growth %-46.75%-128.77%34.08%-72.26%-32.18%1.55%-7.63%17.47%20.26%-45.93%3.24%-188.78%0.67%2.67%-27.4%19.2%38.95%-25.58%-8.6%-
EBITDA-71.32M-82.33M-158.38M-61.42M-101.18M-51.89M-35.11M-36.03M-31.59M-39.75M-55.25M-34.04M-47.77M-15.4M-16.59M-17.5M-13.07M-16.1M-27.58M-21.39M-20.2M
EBITDA Margin %-84.47%-96.48%-90.79%-57.76%-103.3%-39.74%-25.42%-30.73%-27.97%-39%-52.9%-29.67%-41.02%-21.63%-31.7%-40.84%-38.94%-63.34%-179.68%-293.99%-315.79%
EBITDA Growth %22.94%48.02%-157.86%39.3%-94.99%-47.78%2.56%-14.06%20.53%28.06%-62.31%28.75%-210.25%7.17%5.23%-33.94%18.81%41.63%-28.93%-5.86%-
D&A (Non-Cash Add-back)5.17M10.98M16.86M15.18M15.03M15.57M15.92M15.8M16.57M18.61M17.94M16.11M4.06M2.55M1.48M1.06M1.5M1.94M1.97M2.14M1.46M
EBIT-80.93M-96.68M-135M-69.64M-188.6M-59.84M-50.53M-62.43M-47.53M-57.98M-74.36M-48.98M-52.36M-16.38M-18.26M-19.2M-14.66M-16.3M-27.61M-22.56M-21.29M
Net Interest Income10.05M9.15M16.88M1M-2.1M-3.82M-3.57M-4.28M-13.89M-5.82M-5.82M-5.81M-5.34M-14K-628K-3.1M-2.16M-2.84M-1.26M-1.65M-1.7M
Interest Income10.05M9.18M20.2M5.57M2.23M00000000000037K766K1.14M565K
Interest Expense5K26K3.32M4.57M4.33M3.82M3.57M4.28M13.89M5.82M5.82M5.81M5.34M14K628K3.1M2.16M2.88M2.03M2.79M2.26M
Other Income/Expense3.46M-3.4M36.92M2.4M-76.72M3.8M-3.06M-14.87M-13.26M-5.44M-6.99M-4.63M-5.87M2.26M-817K-3.74M-2.25M-1.14M-103K-1.82M-1.89M
Pretax Income-73.03M-96.7M-138.31M-74.2M-192.93M-63.66M-54.1M-66.7M-61.42M-63.8M-80.18M-54.79M-57.7M-15.69M-18.89M-22.3M-16.82M-19.18M-29.65M-25.35M-23.55M
Pretax Margin %-86.5%-113.33%-79.29%-69.78%-196.97%-48.75%-39.16%-56.89%-54.37%-62.59%-76.76%-47.76%-49.55%-22.03%-36.09%-52.03%-50.12%-75.47%-193.17%-348.4%-368.13%
Income Tax-35.8M-37.88M573K452K-2.83M-4.42M-1.08M-1.92M-2.41M-3.26M-4.19M-1.48M-4.88M137K136K166K83K-50K-147K105K194K
Effective Tax Rate %49.03%39.17%-0.41%-0.61%1.47%6.95%2%2.87%3.92%5.12%5.23%2.69%8.45%-0.87%-0.72%-0.74%-0.49%0.26%0.5%-0.41%-0.82%
Net Income-39.21M-74.9M-138.88M-74.66M-190.1M-59.24M-53.02M-64.79M-59.01M-60.53M-75.98M-53.31M-52.83M-15.82M-19.02M-22.47M-16.9M-19.13M-29.5M-25.45M-23.55M
Net Margin %-46.44%-87.77%-79.62%-70.2%-194.08%-45.36%-38.38%-55.26%-52.24%-59.38%-72.75%-46.48%-45.36%-22.23%-36.35%-52.42%-50.36%-75.27%-192.21%-349.84%-368.13%
Net Income Growth %69.42%46.07%-86.03%60.73%-220.91%-11.73%18.17%-9.79%2.51%20.33%-42.52%-0.92%-233.9%16.83%15.34%-32.94%11.64%35.16%-15.91%-8.06%-
Net Income (Continuing)-37.23M-58.83M-138.88M-74.66M-190.1M-59.24M-53.02M-64.79M-59.01M-60.53M-75.98M-53.31M-52.83M-16.53M-19.02M-22.47M-16.9M-19.13M-29.5M-25.45M-23.55M
Discontinued Operations0-16.07M0000000000000000000
Minority Interest000000000000000000000
EPS (Diluted)-0.10-0.20-0.52-0.94-2.43-0.78-0.74-0.97-1.49-1.84-2.62-1.86-1.90-0.62-0.86-1.26-0.89-11.02-17.85-13.47-12.46
EPS Growth %67.73%61.54%44.68%61.32%-211.54%-5.41%23.71%34.9%19.02%29.77%-40.86%2.11%-206.45%27.91%31.75%-41.57%91.92%38.26%-32.52%-8.11%-
EPS (Basic)--0.20-0.52-0.94-2.43-0.78-0.74-0.97-1.49-1.84-2.62-1.86-1.90-0.62-0.86-1.26-0.89-11.02-17.85-13.47-12.46
Diluted Shares Outstanding393.56M381.62M352.67M79.16M78.31M75.79M72.04M66.78M39.65M32.98M29.01M28.71M27.77M25.48M22.14M17.85M18.98M1.74M1.65M1.89M1.89M
Basic Shares Outstanding393.56M381.62M352.67M79.16M78.31M75.79M72.04M66.78M39.65M32.98M29.01M28.71M27.77M25.48M22.14M17.85M18.98M1.74M1.65M1.89M1.89M
Dividend Payout Ratio---------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Persistent operating losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Stabilizing After Steep Decline

Based on reported quarterly figures, LAB revenue fell from $46.7M in 2024Q4 to $19.4M in 2026Q3, with the most recent quarters showing near-flat sequential movement around $19M to $21M, suggesting the base may be stabilizing at a far lower level.

The 2024Q4 revenue peak appears to have been elevated by items that did not recur, as quarterly revenue stepped down sharply in 2025 and has held within a narrow band since. Year-over-year comparisons are flattered in some quarters and punished in others, so the sequence rather than any single growth rate better reflects the underlying trend. Investors should monitor whether revenue can grow off this reset base, since the reported figures alone do not establish a durable recovery.

Gross Margin Volatility Without Clear Trend

As reported in the income statements, LAB gross margin ranged from 43.0% to 55.9% across the ten quarters, with the latest quarter at 55.9% compared with 46.9% a year earlier, indicating meaningful quarter-to-quarter variability in product mix or cost absorption.

Gross margin has swung widely rather than following a steady expansion path, which suggests sensitivity to revenue scale and cost absorption at a small revenue base. The 2026Q3 margin sits at the top of the observed range, but one quarter is insufficient to establish a structural improvement. Relative to peers such as PACB at 31.7% and NTRA at 64.8%, LAB's gross margin is mid-range, which implies its pricing power is neither clearly superior nor weak.

Operating Losses Persist Despite Cost Cuts

Based on reported figures, LAB operating loss was -$19.8M in 2026Q3 against -$32.8M in 2024Q4, while SG&A fell from $37.6M to $16.8M, indicating overhead reduction has been substantial yet has not closed the gap to profitability.

Operating expenses have been cut materially, yet operating margin remained deeply negative at -102.0% in the latest quarter, meaning revenue scale has not yet caught up with the remaining cost base. The reduction in SG&A is significant, but the operating loss in 2026Q3 is still larger in absolute terms than gross profit, indicating operating leverage is not yet working in the company's favor. Further analysis is warranted to determine how much of the remaining cost base is fixed versus discretionary.

Net Income Swings Driven by Non-Operating Items

As reported, LAB net income moved from -$45.2M in 2026Q1 to +$13.5M in 2026Q3 while operating income remained negative in both periods, suggesting the bottom-line swings are driven by items outside core operations.

The divergence between operating loss and positive net income in 2026Q3, and the reverse pattern in other quarters, indicates that non-operating items such as gains, losses, or tax effects are materially influencing reported earnings. Net margin figures like 69.6% and -177.4% therefore reflect noise more than operating performance. Stock-based compensation of $3.7M to $12.9M per quarter is also a non-trivial share of the cost base, which warrants further investigation into its effect on reported earnings quality.

Positive Quarter May Not Signal Recovery

The strongest bear case rests on the fact that LAB reported positive net income of $13.5M in 2026Q3 while operating margin remained at -102.0%, a pattern that short-sellers would likely flag as non-recurring rather than evidence of sustainable profitability.

A single quarter of positive net income, set against sustained negative operating income and stagnant revenue around $19M to $21M, may be interpreted as a one-off rather than a turn in the business. Revenue has not demonstrated consistent growth since the 2024 peak, and the operating loss remains the dominant feature of the income statement. Investors should monitor whether operating losses narrow across several consecutive quarters before attributing the latest result to improving fundamentals.

LAB — Frequently Asked Questions

Quick answers to the most common questions about buying LAB stock.

What was Standard BioTools Inc.'s (LAB) revenue in 2025?

For fiscal year 2025, Standard BioTools Inc. (LAB) reported total revenue of $85.3M. This represents a 1233.7% increase compared to $6.4M in 2006.

Is Standard BioTools Inc. (LAB) profitable?

Standard BioTools Inc. (LAB) reported a net loss of $74.9M for the fiscal year ending 2025.

What is Standard BioTools Inc.'s operating profit margin?

Standard BioTools Inc. (LAB) reported an operating income of $-93.3M, resulting in an operating profit margin of -109.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Standard BioTools Inc.'s gross profit and gross margin?

Standard BioTools Inc. (LAB) generated $42.5M in gross profit for the year, representing a gross profit margin of 49.9%. This demonstrates the company's core pricing power and production efficiency.